文献速递间质性肺疾病

特发性肺纤维化的综合与个体化患者管理:优化诊断、预后与治疗策略

Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment.
PubMed 文献 · Chest · 2017-01-01

本文综述特发性肺纤维化(IPF)的诊疗进展,指出其在美国医保人群中患病率14年间翻倍。2015年ATS指南更新后,推荐吡非尼酮、尼达尼布和抗酸治疗,不再推荐标准免疫抑制治疗。强调早期诊断、早期治疗及多学科团队参与,并建议早期转诊至间质性肺病中心。

要点

  • IPF诊断需多学科团队,核心是排除系统性疾病和暴露,并识别UIP模式。
  • 2015年ATS指南条件性推荐吡非尼酮、尼达尼布和抗酸治疗,不推荐标准免疫抑制治疗。
  • 早期诊断和早期启动治疗对长期临床结局至关重要,个体化治疗可提高依从性。

核心结论

  • IPF是病因不明的慢性进行性纤维化肺病,早期诊断和早期治疗对改善长期结局至关重要。

研究设计与样本

  • 本文为综述,总结IPF的诊断、预后和治疗策略,并解读2015年ATS指南更新。

主要发现

  • IPF是美国成人中最常见的特发性间质性肺炎,过去14年美国医保受益人患病率增加超过一倍。

关键数值与推荐

  • 2015年ATS指南条件性推荐吡非尼酮、尼达尼布和抗酸治疗,不推荐标准免疫抑制治疗。
  • 诊断核心为排除系统性疾病和暴露,并通过高分辨率CT或外科肺活检识别普通型间质性肺炎(UIP)模式。

临床怎么用

  • 对疑似IPF患者应尽早转诊至间质性肺病中心,以获取综合诊疗、临床试验和移植评估机会。
  • 治疗应个体化,兼顾药物依从性和健康行为改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As seen in this CME online activity (available at http://courses.elseviercme.com/chest16/647e), idiopathic pulmonary fibrosis (IPF) is a specific form of chronic progressive fibrotic lung disease of unknown cause. It is the most common form of idiopathic interstitial pneumonia in adults. Its prevalence among US Medicare beneficiaries has more than doubled in the past 14 years. With the approval of two agents that reduce functional decline and disease progression, and the 2015 update of the American Thoracic Society guidelines on the treatment of IPF, the options for appropriate clinical management of the disease have become well defined. Early diagnosis and early initiation of treatment are of critical importance for long-term clinical outcomes. The diagnostic process, which may require a multidisciplinary team of experts, is centered on excluding systemic diseases and exposures and identifying a pattern of usual interstitial pneumonia on high-resolution CT or surgical lung biopsy results. Familiarity with the 2015 American Thoracic Society guidelines is critical with respect to both the treatments that the guidelines recommend and those that they advise against. Standard immunosuppressive therapy is no longer indicated, whereas pirfenidone, nintedanib, and antacid therapy are all conditionally recommended for use. Individualizing treatment is important in light of potential improved adherence to both drug therapy and health behaviors. An early referral to an interstitial lung disease center offers the advantages of comprehensive diagnostic and disease-management expertise, potential enrollment in a clinical trial, and evaluation for transplantation.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Martinez FJ, Flaherty KR. Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment. Chest. 2017. PMID: 28483105. doi:10.1016/j.chest.2017.03.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。